Phio Pharmaceuticals (PHIO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

PHIO Phio Pharmaceuticals

Watchlist

1.7600
+0.0200+1.15%

Close Dec 20 16:00 ET

1.6601
-0.0999-5.68%

Post 19:57 ET

2.63MMarket Cap-0.18P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Phio Pharmaceuticals Announces $1.15M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BenzingaDec 19 14:32 ET
Express News | Phio Pharmaceuticals Corp: Intratumoral Injections Have Been Well Tolerated
ReutersDec 19 08:42 ET
Express News | Phio Pharmaceuticals: Positive Safety Monitoring Committee Recommendation to Continue to Third Dose Cohort in Its Clinical Study of Ph-762
ReutersDec 19 08:40 ET
Express News | Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial
BenzingaDec 19 07:50 ET
Phio Pharmaceuticals Announces Publication In Frontiers In Immunology Announces Its Manuscript, Self-Delivering RNAi Immunotherapeutic PH-762 Silences PD-1 To Generate Local And Abscopal Anti-Tumor Efficacy, Has Been Published In The December, 2024...
BenzingaDec 12 09:32 ET
Phio Pharmaceuticals Completes Enrollment In Second Cohort In Phase 1b Dose-Escalating Clinical Study
BenzingaNov 19 07:48 ET

Comments

103622690 DK

23 hours ago

$Phio Pharmaceuticals (PHIO.US)$
In a concurrent private placement to the same institutional investors, we are also issuing unregistered warrants to purchase up to 437,192 shares of Common Stock (the “Private Warrants”). For each share of Common Stock issued in this registered offering, an accompanying Private Warrant will be issued to the purchaser thereof. Each Private Warrant will be exercisable for one share of Common Stock at an exercise price of $2.51 per share, will be immediately exerc...

Jaguar8

Yesterday 03:29

NEWS

$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Thursday, 19th December at 2:28 pm
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer cells, today announced t...

Trytosaveabit

Dec 19 06:52

News

$Phio Pharmaceuticals (PHIO.US)$ Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial To Evaluate The Safety And Tolerability Of PH-762 For Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And Stage 4 Merkel Cell Carcinoma

Jaguar8

Dec 19 06:46

NEWS

$Phio Pharmaceuticals (PHIO.US)$
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
Thursday, 19th December at 7:45 am
Phio's Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration
Marlborough, Massachusetts--(Newsfile Corp. - December 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage bio...

Stock_Drift

Dec 12 09:11

$Phio Pharmaceuticals (PHIO.US)$

Heat List

Overall

No Data